不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
加拿大复发/难治性大 B 细胞淋巴瘤患者中阿基仑赛与标准治疗的比较：ZUMA-7 试验的成本效果分析
英文原题：Axicabtagene ciloleucel compared to standard of care in Canadian patients with relapsed or refractory large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial.
查看英文原题
Axicabtagene ciloleucel compared to standard of care in Canadian patients with relapsed or refractory large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
在二线治疗中使用 axi-cel 是一种具有成本效益的选择，可满足加拿大 r/r LBCL 患者重要的未满足临床需求。
中文摘要
方法
采用三种健康状态的分割生存模型，从加拿大医疗卫生系统角度估算axi-cel与SOC的成本效益。临床结局依据ZUMA-7试验。模型计算预期质量调整生命年（QALY）、总成本和增量成本效果比（ICER）。
结果
在终生时间范围内，模型估算axi-cel和SOC的QALY分别为9.48和7.25，总成本分别为569,168美元和337,906美元，对应ICER为每QALY 103,810美元。对SOC组中随后接受细胞治疗的较大比例患者进行调整后，ICER降至每QALY 78,555美元。
结论
对于加拿大r/r LBCL患者，二线axi-cel治疗是一种具有成本效益的选择，可满足重要的未满足临床需求。
展开英文摘要原文
METHODS
A 3-health state partitioned-survival model was used to estimate the cost-effectiveness of axi-cel vs. SOC from a Canadian healthcare system perspective. Clinical outcomes were informed by ZUMA-7. The model calculated expected quality-adjusted life years (QALYs), total costs, and the incremental cost-effectiveness ratio (ICER).
RESULTS
Over a lifetime horizon, the model estimated a total of 9.48 and 7.25 QALYs, and total costs of $569,168 and $337,906 for axi-cel and SOC, respectively, resulting in an ICER of $103,810/QALY. When adjusting for the substantial proportion of patients in the SOC arm who received cellular therapy as subsequent treatment, the ICER was reduced to $78,555/QALY.
CONCLUSIONS
Treatment with axi-cel in 2L is a cost-effective option that addresses an important unmet clinical need for Canadian patients with r/r LBCL.
论文信息
- 作者
- Kuruvilla J、Sehn LH、Whitney S、Patel AR、Cameron H、Reid GGJ
- 第一作者单位
- Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.Canada
- 通讯作者单位
- Kite, a Gilead Company, Santa Monica, CA, USA.United States
- 期刊
- Journal of medical economics2025 Dec
- 原文标识
- PubMed 40314691 · DOI 10.1080/13696998.2025.2498853